ImmunoGen Announces Webcast of Presentation at Jefferies 2018 Global Healthcare Conference
May 30 2018 - 4:15PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that the Company will present at the upcoming
Jefferies 2018 Global Healthcare Conference. The presentation is
scheduled for 1:30 p.m. ET on June 7, 2018.
A webcast of the presentation will be accessible live through
the “Investors” section of the Company’s website,
www.immunogen.com; a replay will be available in the same location
for approximately two weeks.
ABOUT IMMUNOGENImmunoGen is developing the next
generation of antibody-drug conjugates (ADCs) to improve outcomes
for cancer patients. By generating targeted therapies with enhanced
anti-tumor activity and favorable tolerability profiles, we aim to
disrupt the progression of cancer and offer our patients more good
days. We call this our commitment to “target a better now.” Our
lead product candidate, mirvetuximab soravtansine, is in Phase 3
study for folate receptor alpha (FRα)-positive platinum-resistant
ovarian cancer, and in Phase 1b/2 testing in combination regimens.
Our novel IGN candidates for hematologic malignancies, IMGN779 and
IMGN632, are in Phase 1 studies.
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180530006121/en/
Investor Relations ContactImmunoGenSarah Kiely,
781-895-0600sarah.kiely@immunogen.comorMedia
ContactImmunoGenCourtney O’Konek,
781-895-0600courtney.okonek@immunogen.comorFTI ConsultingRobert
Stanislaro, 212-850-5657robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024